NewsBenzinga土曜日に報告:アベキシタイドが術後低血糖における第3相LUCIDITY試験の主要評価項目を達成、レベル2/3イベントを週0.55件に抑制し、プラセボの1.24件を上回る改善を示し、治療関連の重篤な有害事象は認められず 土曜日に報告:アベキシタイドが術後低血糖における第3相LUCIDITY試験の主要評価項目を達成、レベル2/3イベントを週0.55件に抑制し、プラセボの1.24件を上回る改善を示し、治療関連の重篤な有害事象は認められず Benzinga 2026.11.16 05:33 (GMT+0) Open on Benzinga Other news South Korean Lawmaker Proposes Virtual Asset AML Bill, Exchanges Face Fines of Up to 100 Million Won Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’ Italian Robotics Startup Mosaico Raises €7.5 Million Seed Round Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply Are Wall Street Analysts Bullish on Eversource Energy Stock? Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events
Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’
Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply
Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events